Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
|Webcasts|February 19, 2020
Supply Chain Models for Global Trials: Singapore as the APAC Gateway to the World
Author(s)Catalent
How can you overcome clinical import and export challenges within the Asia-Pacific region? Join Catalent’s Julie Delaney and Rognvald Lamb as they present the advantages of using Singapore as an APAC clinical supply hub. Live: US & Europe Broadcast: Wednesday, Feb. 19, 2020 at 11am EST | 8am PST | 4pm GMT | 5pm CET Asia-Pacific Broadcast: Thursday, Feb. 20, 2020 at 8:30am IST | 11am CST | 12pm JST On demand available after airing until Feb. 19, 2021 Register free
Register free:
Event Overview:
With an increasing number of clinical studies being conducted in the Asia-Pacific (APAC) region, there is a growing need for streamlining import and export strategies and clinical supply support. Multiple factors, including positive changes in clinical research regulations, reduced costs to run trials, and large urban-centered populations are attracting sponsors to the region.
Singapore has long been a gateway into the region for sponsors, offering well-established regulations and an excellent infrastructure. The city can serve as an ideal hub for the import and export of clinical supplies into and throughout the APAC region.
Register for this webcast to get expert insights on using Singapore as a clinical supply hub.
Key Learning Objectives:
- The economic and regulatory advantages of using Singapore to supply global studies
- Overcoming challenges in running clinical trials in the APAC countries
- Singapore’s import and export capabilities to support the APAC region
- The importance of clinical supply management to optimize strategy and support timely execution of trials
- Customs influence on returns and destructions
Speakers: Julie Delaney, Director, Clinical Supplies and Project Management, APAC, Catalent
Rognvald Lamb, Director, Transportation Services, Clinical Supply Services, Catalent
Time and date:
US & Europe Broadcast: Wednesday, Feb. 19, 2020 at 11am EST | 8am PST | 4pm GMT | 5pm CET
Asia-Pacific Broadcast: Thursday, Feb. 20, 2020 at 8:30am IST | 11am CST | 12pm JST
On demand available after airing until Feb. 19, 2021
Sponsor: Catalent
Register free:
Related to this article
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.